Dr. Ji is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
Endicott St
Danvers, MA 01923Phone+1 978-717-0285Fax+1 603-580-6747
Education & Training
- University of Vermont Medical CenterFellowship, Hematology and Medical Oncology, 2012 - 2015
- Morehouse School of Medicine/CHI St. Vincent's (Hot Springs)Residency, Internal Medicine, 2008 - 2011
- Tianjin Medical UniversityClass of 1998
Certifications & Licensure
- MA State Medical License 2011 - 2025
- NH State Medical License 2015 - 2025
- VT State Medical License 2012 - 2015
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- 94 citationsDouble-Blind Phase III Randomized Trial of the Antiprogestin Agent Mifepristone in the Treatment of Unresectable Meningioma: SWOG S9005.Yongli Ji, Cathryn Rankin, Steven M. Grunberg, Andy Sherrod, Jamshid Ahmadi
Journal of Clinical Oncology. 2015-11-02 - 8 citationsAllosteric PI3Kα Inhibition Overcomes On-target Resistance to Orthosteric Inhibitors Mediated by Secondary PIK3CA Mutations.Andreas Varkaris, Ferran Fece de la Cruz, Elizabeth E Martin, Bryanna L Norden, Nicholas Chevalier
Cancer Discovery. 2024-02-08 - 6 citationsDiscovery and Clinical Proof-of-Concept of RLY-2608, a First-in-Class Mutant-Selective Allosteric PI3Kα Inhibitor That Decouples Antitumor Activity from Hyperinsulinemia.Andreas Varkaris, Ermira Pazolli, Hakan Gunaydin, Qi Wang, Levi Pierce
Cancer Discovery. 2024-02-08
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: